140 related articles for article (PubMed ID: 22422099)
1. Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas.
Yamamoto Y; Maeda Y; Kawai N; Kudomi N; Aga F; Ono Y; Nishiyama Y
Nucl Med Commun; 2012 Jun; 33(6):621-5. PubMed ID: 22422099
[TBL] [Abstract][Full Text] [Related]
2. Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas.
Kawai N; Lin W; Cao WD; Ogawa D; Miyake K; Haba R; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1870-8. PubMed ID: 24781871
[TBL] [Abstract][Full Text] [Related]
3. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis.
Bekaert L; Valable S; Lechapt-Zalcman E; Ponte K; Collet S; Constans JM; Levallet G; Bordji K; Petit E; Branger P; Emery E; Manrique A; Barré L; Bernaudin M; Guillamo JS
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1383-1392. PubMed ID: 28315948
[TBL] [Abstract][Full Text] [Related]
4. ¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.
Hirata K; Terasaka S; Shiga T; Hattori N; Magota K; Kobayashi H; Yamaguchi S; Houkin K; Tanaka S; Kuge Y; Tamaki N
Eur J Nucl Med Mol Imaging; 2012 May; 39(5):760-70. PubMed ID: 22307533
[TBL] [Abstract][Full Text] [Related]
5. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.
Cher LM; Murone C; Lawrentschuk N; Ramdave S; Papenfuss A; Hannah A; O'Keefe GJ; Sachinidis JI; Berlangieri SU; Fabinyi G; Scott AM
J Nucl Med; 2006 Mar; 47(3):410-8. PubMed ID: 16513609
[TBL] [Abstract][Full Text] [Related]
6. Correlation of 4'-[methyl-(11)C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with (11)C-methionine uptake.
Tanaka K; Yamamoto Y; Maeda Y; Yamamoto H; Kudomi N; Kawai N; Toyohara J; Nishiyama Y
Ann Nucl Med; 2016 Feb; 30(2):89-96. PubMed ID: 26511019
[TBL] [Abstract][Full Text] [Related]
7. A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.
Wei Y; Zhao W; Huang Y; Yu Q; Zhu S; Wang S; Zhao S; Hu X; Yu J; Yuan S
PLoS One; 2016; 11(6):e0157606. PubMed ID: 27322586
[TBL] [Abstract][Full Text] [Related]
8. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET.
Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y
Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312
[TBL] [Abstract][Full Text] [Related]
9. Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.
Yamaguchi S; Hirata K; Toyonaga T; Kobayashi K; Ishi Y; Motegi H; Kobayashi H; Shiga T; Tamaki N; Terasaka S; Houkin K
PLoS One; 2016; 11(12):e0167917. PubMed ID: 27936194
[TBL] [Abstract][Full Text] [Related]
10. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma.
Hatakeyama T; Kawai N; Nishiyama Y; Yamamoto Y; Sasakawa Y; Ichikawa T; Tamiya T
Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2009-17. PubMed ID: 18542957
[TBL] [Abstract][Full Text] [Related]
11. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
12. Correlation between hypoxic area in primary brain tumors and WHO grade: differentiation from malignancy using 18F-fluoromisonidazole positron emission tomography.
Kanoto M; Kirii K; Hiraka T; Toyoguchi Y; Sugai Y; Matsuda K; Sakurada K; Sonoda Y; Hatazawa J; Hosoya T
Acta Radiol; 2018 Feb; 59(2):229-235. PubMed ID: 28534419
[TBL] [Abstract][Full Text] [Related]
13. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
14. Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma.
Kawai N; Maeda Y; Kudomi N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
Eur J Nucl Med Mol Imaging; 2011 Mar; 38(3):441-50. PubMed ID: 21072512
[TBL] [Abstract][Full Text] [Related]
15. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O.
Bruehlmeier M; Roelcke U; Schubiger PA; Ametamey SM
J Nucl Med; 2004 Nov; 45(11):1851-9. PubMed ID: 15534054
[TBL] [Abstract][Full Text] [Related]
16. 18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions.
Muzi M; Peterson LM; O'Sullivan JN; Fink JR; Rajendran JG; McLaughlin LJ; Muzi JP; Mankoff DA; Krohn KA
J Nucl Med; 2015 Aug; 56(8):1223-8. PubMed ID: 26112020
[TBL] [Abstract][Full Text] [Related]
17. Characterizing hypoxia in human glioma: A simultaneous multimodal MRI and PET study.
Preibisch C; Shi K; Kluge A; Lukas M; Wiestler B; Göttler J; Gempt J; Ringel F; Al Jaberi M; Schlegel J; Meyer B; Zimmer C; Pyka T; Förster S
NMR Biomed; 2017 Nov; 30(11):. PubMed ID: 28805936
[TBL] [Abstract][Full Text] [Related]
18. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
[TBL] [Abstract][Full Text] [Related]
19. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas.
Swanson KR; Chakraborty G; Wang CH; Rockne R; Harpold HL; Muzi M; Adamsen TC; Krohn KA; Spence AM
J Nucl Med; 2009 Jan; 50(1):36-44. PubMed ID: 19091885
[TBL] [Abstract][Full Text] [Related]
20. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
Li DL; Xu YK; Wang QS; Wu HB; Li HS
Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
